Immunex Corporation

Amgen Inc.

Amnis Corporation

Innunex Corporation

David Haskett Lynch

Mark R Alderson

Charles R Maliszewski

Luis G Borges

William E Ortyn

David Abraham Basiji

Sarah S Bacus

Eugene Maraskovsky

Xiao-Dong Yang

Kenneth Allan Brasel

Hilary Jean McKenna

Gisela Schwab

Pamela Lockbaum

Robert E Miller

This invention provides methods for determining or predicting response to cancer therapy in an individual.

Method for predicting response to epidermal growth factor receptor-directed therapy

Aspects of the present invention encompass the collection of multispectral images from a population of objects, and the analysis of the collected images to measure at least one characteristic of the population, using photometric and/or morphometric features identifiable in the collection of images. In an exemplary application, the objects are biological cells. In a particularly preferred, but not limiting implementation, the plurality of images for each individual object are collected simultaneously. In an empirical study, the characteristic being measured involves the synapse between conjugated cells. The conjugated cells may represent a subpopulation of the overall population of objects that were imaged. In a particularly preferred, yet not limiting embodiment, the present invention enables the quantization of the redistribution of cellular molecules due to the conjugation of different biological cells. Significantly, such quantization is not feasible with standard microscopy and flow cytometry.

Methods for analyzing inter-cellular phenomena

Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.

Methods of using flt3-ligand in the treatment of fibrosarcoma

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

Methods of preparing dendritic cells with flt3-ligand and antigen

The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.

Fas antagonists

Fas antagonists and uses thereof

Human anti-Fas IgG1 monoclonal antibodies

There is disclosed an immunotherapy method for treating an individual with cancer or a viral infection comprising obtaining lymphoid cells previously exposed to a specific antigen, culturing the lymphoid cells ex vivo in a culture medium containing an effective amount of an IL-7 polypeptide or a functional derivative thereof to induce CTL activity in the lymphoid cells and administering the lymphoid cells having CTL activity for cells displaying the specific antigen to an individual.

Adoptive immunotherapy with interleukin-7

Growing community of inventors

Bainbridge Island, WA, United States of America

David Haskett Lynch